These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25457852)

  • 21. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.
    Su TH; Hsu CS; Chen CL; Liu CH; Huang YW; Tseng TC; Liu CJ; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2010; 15(8):1133-9. PubMed ID: 21149920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
    Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
    J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do guidelines preclude hepatitis B patients from receiving treatment?
    Degertekin B; Lok AS
    Hepatology; 2009 Feb; 49(2):700-1; author reply 701-2. PubMed ID: 19177583
    [No Abstract]   [Full Text] [Related]  

  • 26. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral therapy for chronic hepatitis B.
    Jafri SM; Lok AS
    Clin Liver Dis; 2010 Aug; 14(3):425-38. PubMed ID: 20638023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
    Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
    Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 30. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
    Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
    J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose lamivudine and hepatitis B.
    Musher DR; Wasser WG; Saggi SJ
    Am J Gastroenterol; 1999 Nov; 94(11):3372. PubMed ID: 10566751
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B.
    Cheng PN; Tsai HW; Chiu YC; Ho CH; Wu IC; Chang TT
    J Clin Virol; 2013 Aug; 57(4):323-30. PubMed ID: 23731848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
    Lin Q; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
    [No Abstract]   [Full Text] [Related]  

  • 36. Prediction of response to interferon α-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels.
    Ma Q; Qin B; Gong X; Lu X
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):820-4. PubMed ID: 23411867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?].
    Kang K; Kim JH
    Korean J Gastroenterol; 2014 May; 63(5):329-32. PubMed ID: 25007428
    [No Abstract]   [Full Text] [Related]  

  • 39. Telbivudine.
    Dienstag J; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Apr; 6(4):267-8. PubMed ID: 17458000
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical consequences of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Cadranel JF
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S12-6. PubMed ID: 17075489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.